Etoricoxib – 15 years in Russia: the main results in the treatment of rheumatic diseases

Background. According to epidemiological studies, chronic musculoskeletal pain affects more than 30% of people worldwide, causing a huge personal and social burden. Nonsteroidal anti-inflammatory drugs are widely used to treat musculoskeletal pain. The drug etoricoxib, highly selective for COX-2, is characterized by linear pharmacodynamics, that is, its effect directly depends on the dose, and the wide range of doses registered for use (from 30 to 120 mg per day) makes it possible to effectively suppress both acute and chronic pain with various diseases.

Results. This review provides information on the use of etoricoxib in osteoarthritis, particularly of the knee or hip, including in elderly patients; in the treatment of low back pain, one of the most common causes of decreased productivity worldwide; in the treatment of rheumatoid arthritis and ankylosing spondylitis, as well as gout. It has been shown that the selective COX-2 inhibitor etoricoxib has pronounced anti-inflammatory and analgesic activity and has a number of undeniable advantages not only over non-selective COX-1 and COX-2 inhibitors, but also over selective COX-2 inhibitors, being the most highly selective among them. The drug has the same pharmacokinetic parameters in both young patients and the elderly, which simplifies its administration to patients in older age groups, and, in addition, etoricoxib is rapidly absorbed when taken orally. Important characteristics of etoricoxib include its safety in relation to the gastrointestinal tract. The availability of a range of therapeutic doses of etoricoxib makes it possible to effectively treat acute and chronic pain in various diseases affecting the structures of the musculoskeletal system and perioperative pain.

1. Stiller C.-O., Paul Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: Importance of dose – response considerations and fair play in comparative trial. Journal Int Med. 2022; 292: 557-574. DOI: 10.1111/joim.13505.

2. Cohen S. P., Vase L., Hooten W. M. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021; 397 (10289): 2082-2097. DOI: 10.1016/S0140-6736(21)00393-7.

3. Amaech O., McCann Huffman M., Featherstone K. Pharmacologic Therapy for Acute Pain.Am Fam Physician. 2021; 104 (1): 63-72. PMID: 34264611.

4. Martina S., Vesta K., Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005; 39 (5): 854-862. DOI: 10.1345/aph.1E543.

5. Kwiatkowska B., Majdan M., Mastalerz-Migas A., et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017; 55 (6): 290-297. DOI: 10.5114/reum.2017.72626.

6. Palazzo C., Nguyen C., Lefevre-Colau M.-M., Rannou F., Poiraudeau S. Risk factors and burden of osteoarthritis. Ann Phys Rehabil Med. 2016; 59 (3): 134-138. DOI: 10.1016/j.rehab.2016.01.006.

7. Alekseeva L. I. Update of clinical recommendations for the treatment of patients with osteoarthritis in 2019. RMJ 2019; 4: 2-6. www.rmj.ru/archive/klinicheskie-rekomendatsii-i-alg-oritmy-dlya-praktikuyushchikh-vrachey-4-2019/ (In Russ.)

8. Bruyere O., Honvoa G., Veronesec N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism. 2019; 00: 1-14. doi.org/10.1016/j.semarthrit.2019.04.008.

9. Kolasinski S. L., Neogi T., Hochberg M. C., et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020; 72 (2): 149-162. DOI 10.1002/acr.24131.

10. Da Costa B. R., Reichenbach S., Keller N., et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016; 387 (10033): 2093-2105. DOI: 10.1016/S0140-6736(16)30002-2.

11. Zacher J., Feldman D., Gerli R., et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003; 19 (8): 725-736. DOI: 10.1185/030079903125002469.

12. Combe B., Swergold G., McLay J., et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009; 48 (4): 425-432. DOI: 10.1093/rheumatology/kep005.

13. Feng X., Tian M., Zhang W., Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018; 13 (1): e0190798. DOI: 10.1371/journal.pone.0190798.

14. Karateev A. E., Pogozheva E. Yu., Filatova E. S., Amirdzhanova V. N. Endoscopic picture of the upper gastrointestinal tract while taking various non-steroidal anti-inflammatory drugs. Klinicheskaya farmakologiya i terapiya. 2018; 27(4):40-45. https://clinpharm-journal.ru/files/articles/ehndoskopicheskaya-kartina-verhnih-otdelov-zheludochno-kishechnogo-trakta-na-fone-priema-razlichnyh-nesteroidnyh-protivovospalitelnyh-preparatov.pdf?ysclid=ln5yn7y2eh472372745. (In Russ.)

15. Curtis S. P., Ng J., Yu Q., et al. Renal effects of etoricoxib and comparator nonsteroidal antiinf lammatory drugs in controlled clinical trials. Clin Ther. 2004; 26 (1): 70-83. DOI: 10.1016/s0149-2918(04)90007-0.

16. Cannon C. P., Curtis S. P., FitzGerald G. A., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368 (9549): 1771-1781. DOI: 10.1016/S0140-6736(06)69666-9.

17. Curtis S. P., Bockow B., Fisher C., et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord. 2005; 6: 58. DOI: 10.1186/1471-2474-6-58.

18. Reginster J. Y., Malmstrom K., Mehta A., et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007; 66: 945-951. DOI: 10.1136/ard.2006.059162.

19. Song G. G., Seo Y. H., Kim J.-H., et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Z Rheumatol. 2016; 75 (5): 508-516. DOI: 10.1007/s00393-015-0023-9.

20. Huang W.-N., Tim K., Tso T. K. Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly. Bosn J Basic Med Sci. 2018; 18 (1): 87-94. DOI: 10.17305/bjbms.2017.2214.

21. Krum H., Swergold G., Gammaitoni A., et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinf lammatory drugs. Cardiovasc Ther. 2012; 30: 342-50. DOI: 10.1111/j.1755-5922.2011.00283.x.

22. Schwartz J. I., Thach C., Lasseter K. C., et al. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. J Clin Pharmacol. 2007; 47: 1521-1531. DOI: 10.1177/0091270007307878.

23. Wu A., March L., Zheng X., et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020; 8 (6): 299. DOI: 10.21037/atm.2020.02.175.

24. Baron R., Binder A., Attal N., et al. Neuropathic low back pain in clinical practice. Eur J Pain. 2016; 20 (6): 861-873. DOI: 10.1002/ejp.838.

25. Zerbini C., Ozturk Z. E., Grifka J., et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005; 21 (12): 2037-2049. DOI: 10.1185/030079905X75069.

26. Jagannathana H., Thota A., Kumarappab A. K. B., Kishore G. A comparative study of aceclofenac versus etoricoxib in the management of acute low back pain in a tertiary care hospital. J Drug Ass. 2020; 9 (1): 60-65. DOI:10.1080/21556660.2020.1734008.

27. Karateev A.E., Polishchuk E.Yu., Filatova E.S., et al. Results of an open multicenter non-interventional study of the clinical effectiveness and tolerability of ETC for osteoarthritis and nonspecific back pain with additional assessment of the effect of the drug on the "central" manifestations of pain. Sovremennaya revmatologiya. 2022; 16 (2): 34-42. DOI: 10.14412/1996-7012-2022-2-34-42. (In Russ.)

28. Yeole A. B., Lakshmi G. S. R., Selvakumar C. J., et al. Efficacy and Safety of Pregabalin Prolonged Release – Etoricoxib Combination Compared to Etoricoxib for Chronic Low Back Pain: Phase 3, Randomized Study. Pain Ther. 2022; 11: 1451-1469. DOI: 10.1007/s40122-022-00437-2.

29. Curtis S. P., Maldonado-Cocco J., Losada B. R., et al. Treatment with etoricoxib (MK-0663), a COX-2-selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis. Ann Rheum Dis. 2001; 60 (Suppl 1): A457.2-A457. DOI:10.1136/annrheumdis-2001.1159.

30. Collantes E., Curtis S. P., Lee K. W., et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002; 3: 10. DOI: 10.1186/1471-2296-3-10.

31. Matsumoto A. K., Melian A., Mandel D. R., et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol. 2002; 29 (8):1623-1630. PMID: 12180720.

32. Bickham K., Kivitz A. J., Mehta A., et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016; 17: 331. DOI: 10.1186/s12891-016-1170-0.

33. Feng X., Tian M., Wei Zhang W., Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018; 13 (1):e0190798. DOI: 10.1371/journal.pone.0190798.

34. Chen AI., Lee Y.-H., Perng W.-T., et al. Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study. Front Neurol. 2022; 13: 1018521. DOI: 10.3389/fneur.2022.1018521.

35. Schwartz J. I., Agrawal N. G. B., Wong P. H., et al. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol. 2009; 49 (10): 1202-1209. DOI: 10.1177/0091270009338939.

36. Kvien T. K., Greenwald M., Peloso P. M., et al. Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. BMC Musculoskelet Disord. 2015; 16: 26. DOI: 10.1186/s12891-015-0468-7.

37. Sofia Ramiro S., Nikiphorou E., Sepriano A., et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023; 82: 19-34. DOI: 10.1136/ard-2022-223296.

38. Van der Heijde D., Baraf H. S. B., Ramos-Remus C., et al. Evaluation of the Efficacy of Etoricoxib in Ankylosing Spondylitis Results of a Fifty-Two-Week, Randomized, Controlled Study. Arthr Rheum. 2005; 52 (4): 1205-1215. DOI: 10.1002/art.20985.

39. Balazcs E., Sieper J., Bickham K., et al. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2016; 17 (1): 426. DOI: 10.1186/s12891-016-1275-5.

40. Kristensen L. E., Jakobsen A. K., Askling J., et al. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinf lammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2015; 67 (8): 1137-1149. DOI: 10.1002/acr.22555.

41. Wang R., Dasgupta A., Ward M. M. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016; 75 (6): 1152-1160. DOI: 10.1136/annrheumdis-2015-207677.

42. Rubin B. R., Burton R., Navarra S., et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004; 50 (2): 598-606. DOI: 10.1002/art.20007.

43. Navarra S., Rubin B. R., Yu Q., et al. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Curr Med Res Opin. 2007; 23 (7): 1685-1691. DOI: 10.1185/030079907x210750.

44. Lin T.-M., Chi J.-E., Chang C.-C., Kang Y.-N. Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A meta-analysis of randomized controlled trials. J Pain Res. 2018; 12: 83-91. DOI: 10.2147/JPR.S186004.

45. Xu L., Liu S., Guan M., Xue Y. Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial. Med Sci Monit. 2016; 22: 810-817. DOI: 10.12659/msm.895749.

46. Li M., Yu C., Zeng X. Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. BMJ Open. 2020; 10 (9): e036748. DOI: 10.1136/bmjopen-2019-036748.

47. Eliseev M. S., Barskova V. G. The use of etoricoxib in patients with gout in real clinical practice. Sovremennaya revmatologiya. 2013. 7 (2): 52-56. DOI: 10.14412/1996-7012-2013-2382. (In Russ.)

48. Clarke R., Derry S., Moore R. A., McQuay H. J. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD004309. DOI: 10.1002/14651858.CD004309.pub2.

49. Clarke R., Derry S., Moore R. A. Single dose oral etoricoxib for acute postoperative pain in adults (Review). Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD004309. DOI: 10.1002/14651858.CD004309.pub4.